Histone H3.3-K27M Neoantigen Vaccine - TCRCure Biopharma
Latest Information Update: 28 Apr 2024
At a glance
- Originator TCRCure Biopharma
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Diffuse intrinsic pontine glioma
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Diffuse intrinsic pontine glioma(First-line therapy, In adolescents, In children, In adults) in China (SC, Injection)
- 02 Jun 2023 Adverse events and efficacy data from a phase I trial in Diffuse intrinsic pontine glioma presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 14 Apr 2023 Adverse events and efficacy data from a phase I trial in Diffuse intrinsic pontine glioma presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)